Ovarian Cancer Maintenance Treatment
Listing Websites about Ovarian Cancer Maintenance Treatment
Maintenance therapy for ovarian cancer
(8 days ago) Maintenance therapy for ovarian cancer. Maintenance therapy may be given to some women after they complete chemotherapy treatment to decrease the chance that the cancer will come back, or to delay the cancer from coming back.Two types of targeted therapies are used for maintenance therapy, Avastin (bevacizumab) and PARP inhibitors.. The choice …
Current Ovarian Cancer Maintenance Strategies and
(3 days ago) While ovarian cancer typically responds well to front line treatment, many patients will relapse within 5 years. Treatment options are less effective at each recurrence highlighting the need for novel maintenance therapies. PolyADP-ribose polymerase (PARP) inhibitors have recently gained approval in ovarian cancer maintenance.
How Do Ovarian Cancer Maintenance Treatments Work
(5 days ago) PARP inhibitors that may be used for ovarian cancer maintenance treatment include Zejula (niraparib), Rubraca (rucaparib), and Lynparza (olaparib). Another method of DNA repair uses BRCA1 and BRCA2 genes. Some people have mutations in the BRCA genes that prevent this pathway from working well.
What To Expect From Ovarian Cancer Maintenance Treatment
(2 days ago) Alternately, maintenance treatment may help shrink tumors in advanced ovarian cancer or stop the cancer from getting worse. Ovarian cancer maintenance treatment may include the same chemotherapy drugs a person received during their initial treatment, or it may involve starting new medications.
The Role of Maintenance Therapy in Ovarian Cancer
(1 days ago) AO The general idea behind maintenance therapy is to keep the cancer under control for as long as possible after initial treatment. Although maintenance therapy in oncologic malignancies is not a new concept, it is relatively new in ovarian cancer and other solid tumors. The first agent to receive approval from the US Food and Drug
Maintenance Therapy for Advanced Ovarian Cancer
(3 days ago) Following the primary treatment of ovarian cancer with surgery and chemotherapy the doctor may recommend additional treatment with “maintenance therapy.” The goal of maintenance therapy is to “maintain” a remission or prevent or delay the cancer's return if the cancer is in remission after initial treatment.
Rucaparib Approved as Maintenance Therapy for Ovarian Cancer
(9 days ago) The Food and Drug Administration (FDA) has expanded the approval of the targeted therapy rucaparib (Rubraca) for the treatment of women with ovarian cancer.. The approval covers the use of rucaparib as a follow-on, or maintenance, treatment for women whose ovarian cancer has returned after their initial treatment and whose tumors then …
How Maintenance Therapy for Ovarian Cancer Works
(2 days ago) Maintenance therapy for ovarian cancer is medication that’s given to prevent ovarian cancer from coming back after initial treatment with chemotherapy. The goal is to increase the amount of time
Targeted Therapy for Ovarian Cancer
(5 days ago) Olaparib and rucaparib can be used to treat advanced ovarian cancer that has previously been treated with 2 or 3 chemotherapy drugs. Olaparib can be used with bevacizumab (see above) as maintenance treatment in women whose cancers have shrunk quite a bit with chemotherapy containing carboplatin or cisplatin. In women without a BRCA mutation: If
How Maintenance Therapy for Ovarian Cancer Works
(2 days ago) Maintenance therapy for ovarian cancer is medication that’s given to prevent ovarian cancer from coming back after initial treatment with chemotherapy. The goal is to increase the amount of time between initial treatment and recurrence. The Food and Drug Administration (FDA) has approved the following treatments for ovarian cancer maintenance
Ovarian Cancer: What Is Maintenance Treatment?
(6 days ago) After chemotherapy, maintenance treatment is given to try to stop ovarian cancer from coming back. The goal of maintenance treatment is to keep ovarian cancer under control for as long as possible after first treatment and to prevent or delay cancer from returning. Maintenance treatment may even turn a temporary remission into permanent remission.
Ovarian Cancer Treatment Options Ovarian Cancer
(Just Now) Today, due to treatment advances, some people with ovarian cancer receive maintenance medication after chemotherapy. Studies indicate that maintenance therapy can help prevent or delay a recurrence of ovarian cancer. Here, we’ll explore this ovarian cancer treatment option compared to the “watch and wait” method.
New Treatments for Ovarian Cancer in 2020 - Cancer Commons
(4 days ago) The American Cancer Society estimates that, in 2020, about 21,750 American women will be diagnosed with ovarian cancer and 13,940 women will die from the disease. Factors associated with increased risk of ovarian cancer include family history of ovarian cancer, abnormalities in BRCA genes, age (about half of all ovarian cancer patients are
Rucaparib maintenance treatment for recurrent ovarian
(1 days ago) ARIEL3 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance treatment setting versus placebo could be considered a new standard of care for women with platinum-sensitive ovarian cancer following a complete or partial response to second-line or later platinum-based chemotherapy.
Role of Olaparib as Maintenance Treatment for Ovarian
(3 days ago) Introduction. Ovarian cancer is the seventh most common cancer in women worldwide and is the leading cause of death from gynecologic cancers in high-income countries. 1, 2 The five year survival rate in the United States is 48% and the proportion of women dying from their disease has not improved substantially over time as compared to other prevalent …
Ovarian Cancer Recurrence and Treatment OCRA
(2 days ago) Researchers have made significant advances in maintenance therapies in recent years, which means more people are managing ovarian cancer as a chronic disease for longer periods of time, and there are women who have had a recurrence, who then go on to be NED (No Evidence of Disease). Treatment for Ovarian Cancer Recurrence.
Maintenance chemotherapy for ovarian cancer Cochrane
(1 days ago) However, 75% of the women who respond to initial treatment will relapse within 18 to 28 months and only 20% to 40% of all women will survive beyond five years.Some doctors suggest giving maintenance chemotherapy for epithelial ovarian cancer. Maintenance chemotherapy refers to the chemotherapy given to women who have achieved remission after
FDA approves olaparib plus bevacizumab as maintenance
(7 days ago) FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers for first-line maintenance …
Letrozole may be a valuable maintenance treatment in high
(1 days ago) Objectives: Endocrine therapy is used as maintenance in estrogen receptor (ER) positive breast cancers and has been proposed in low-grade serous ovarian cancers (LGSOC). Here we examine a rationale for its use as maintenance in high-grade serous ovarian cancers (HGSOC). Methods: We accessed the TCGA PANCAN dataset to evaluate the expression of ESR1.
PARP Inhibitors as Initial Treatment for Ovarian Cancer
(9 days ago) Standard initial treatment for women with newly diagnosed advanced ovarian cancer typically includes first-line therapy with a combination of surgery and chemotherapy, sometimes followed by maintenance therapy—an additional treatment intended to help prevent the cancer from coming back. But for most patients, the cancer still returns within 3
Maintenance Therapy for Recurrent Ovarian Cancer
(8 days ago) Key Takeaways. Maintenance therapy for ovarian cancer has been shown to be effective in first-line and recurrent settings; its use is rapidly expanding and continues to evolve as new data emerge.
Assessment Tool for Maintenance Therapy in Ovarian Cancer
(Just Now) In advanced ovarian cancer, genetic testing rates hover around 50%.1 Only 49% of patients received maintenance therapy in second line or greater therapy.2 Current rates warrant improved methods and practices to enable professionals to both identify and offer PARP-Inhibitors to appropriate patients at the right time. Please utilize instructions below to help with your patients.
What is Maintenance Therapy? ZEJULA (niraparib)
(9 days ago) maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that comes back. ZEJULA is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy
What Patients With Ovarian Cancer Should Know About
(2 days ago) Maintenance therapy is meant to prevent relapse after a patient with ovarian cancer received their main treatment. Here’s an overview of what patients should know. When a patient is diagnosed with ovarian cancer, their initial treatment typically consists of a combination of surgery and chemotherapy, after which most enter remission.
FDA approves olaparib tablets for maintenance treatment in
(9 days ago) On Aug. 17, 2017, the U.S. Food and Drug Administration granted regular approval to olaparib tablets (Lynparza, AstraZeneca) for the maintenance treatment of adult patients with recurrent
A Study in Ovarian Cancer Patients Evaluating Rucaparib
(7 days ago) This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of …
Treatment Considerations for PARP - Cancer Network
(4 days ago) Treatment Considerations for PARP Inhibitors in First-Line Maintenance Therapy in Patients With Advanced Ovarian Cancer April 22, 2021 This article reviews emerging evidence on PARP inhibitors as first-line maintenance treatment options after chemotherapy and features expert insights from Rebecca Previs, MD.
PARP Inhibitors and Ovarian Cancer OCRA
(4 days ago) However, the drugs are also now prescribed as a maintenance treatment — this means they are given to patients with advanced epithelial cancers and high-grade serous ovarian cancer after chemotherapy has already decreased the size of their tumor. Studies have shown that this can delay or prevent recurrence of ovarian cancer. Taking PARP Inhibitors
Maintenance Treatment of Newly Diagnosed Advanced Ovarian
(5 days ago) Advanced epithelial ovarian cancer has a poor prognosis, but targeted therapies have been developed and are providing new hope. We reviewed recent results with PARP inhibitors as treatment and/or maintenance therapy following chemotherapy in newly diagnosed advanced ovarian cancer.
Maintenance Olaparib in Patients with Newly Diagnosed
(1 days ago) QUICK TAKE Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer 02:12. Standard therapy for patients with newly diagnosed advanced ovarian cancer consists of cytoreductive
Recurrence in Ovarian Cancer ‐ Our Way Forward
(5 days ago) Once ovarian cancer recurs, the objective is clear: to extend the time between future recurrences. After a woman has been retreated with chemotherapy and her disease has responded (partially or completely), there are two different treatment approaches to take: observe the disease, also referred to as “watch and wait,” or “maintenance” treatment to extend the …
Penson Provides a Snapshot View of Switch Maintenance
(8 days ago) Penson Provides a Snapshot View of Switch Maintenance Therapy Selection in Recurrent Ovarian Cancer. Richard Penson, MD, MBBS, discusses how he makes treatment decisions for maintenance therapy in
Tweet Chat Recap: Westin Discusses Deciding on Initial
(Just Now) 2 days ago · We have great data now for a PARP maintenance with PARP inhibition in any woman with ovarian cancer, but it does seem that certainly having the biomarker matters. So, women that have either a germline or somatic BRCA mutation benefit the most from the use of a PARP inhibitor in the maintenance setting.
PARP Inhibitors for Ovarian Cancer: Uses, Effectiveness
(8 days ago) PARP inhibitors are a promising treatment for ovarian cancer. They work by blocking an enzyme that cells use to repair DNA damage. They can be used as a cancer treatment by stopping cancer cells
Using PARP Inhibitors in Frontline Maintenance Therapy for
(8 days ago) The use of PARP inhibitors in frontline maintenance therapy has greatly reduced the risk of recurrence in patients with ovarian cancer. Ovarian cancer is the leading cause of mortality among gynecologic cancers in the United States, 1 expected to result in roughly 13,940 deaths in 2020. 2 Between 2008 and 2017, mortality decreased by 2.3% per
Not On My Watch: A Call For Change in Ovarian Cancer Care
(9 days ago) More than 22,000 women are diagnosed with ovarian cancer each year 1 — a disease that affects approximately 222,000 women in the US. 3 Sadly, ovarian cancer signs and symptoms are hard to recognize, so women are often diagnosed at later stages with advanced disease. 4,5 For these women, nearly 85% will see the cancer return in their lifetime 2 —known as …
A Study of IMP4297 as Maintenance Treatment Following
(7 days ago) A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer (FLAMES) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Maintenance Olaparib Provides Long-Term PFS Benefit in
(8 days ago) The progression-free survival (PFS) benefit observed with olaparib maintenance persists after treatment completion in patients with advanced ovarian cancer, according to research published in The
Targeted therapies ovarian cancer Ovarian Cancer Action
(8 days ago) Ovarian cancer drug: Niraparib. Niraparib (also known as Zejula) is a maintenance treatment for ovarian cancer. This means it doesn’t cure ovarian cancer but it does prevent its progression. By delaying the spread of the disease, Niraparib can help women feel better and live healthier lives for longer, experiencing reduced symptoms.
Ovarian Cancer Maintenance Resources Rubraca® (rucaparib)
(9 days ago) INDICATIONS . Rubraca is indicated: for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Benefits & risks of treatment for ovarian cancer Avastin
(6 days ago) Avastin ® (bevacizumab), in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery.. Avastin is used with chemotherapy to treat 2 different types of recurrent ovarian cancer: platinum-sensitive and …
Practice Pearl 2: Educating Patients on Maintenance
(1 days ago) Practice Pearl 2: Educating Patients on Maintenance Therapy in Ovarian Cancer. January 7, 2022. Jennifer MacDonald, PharmD, BCOP , Sarah Hayward, PharmD, BCOP , Bradley J. Monk, MD, FACS, FACOG. Experts in gynecologic oncology provide insight on educating patients with ovarian cancer on the duration of maintenance therapy.
Homologous Recombination Deficiency: Concepts, Definitions
(2 days ago) For the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with HRD-positive status defined by either: 1) a deleterious or suspected deleterious BRCA mutation, and
Managing advanced (stage II-IV) ovarian cancer
(7 days ago) Woman with advanced (stage II-IV) ovarian cancer. 1. 1 - N/A. Interim treatment regimens during the COVID-19 pandemic. 2. 2 - interim treatment regimens during the covid 19 pandemic. Primary surgery. 3. 3 - primary surgery.
How long can I take Avastin for ovarian cancer?
(6 days ago) Indication Ovarian Cancer (OC) Avastin, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery.